Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk

Different Oral Antithrombotic Therapy for the Treatment of Ventricular Thrombus: An Observational Study from 2010 to 2019

(2022) Qing Yang et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China

(2021) Hongtao Wei et al.   BMC HEALTH SERVICES RESEARCH

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis

(2021) Januar Wibawa Martha et al.   Frontiers in Cardiovascular Medicine

A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation

(2020) Renato D. Lopes et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Incidence and outcomes of patients with atrial fibrillation and major bleeding complications: from the TREAT-AF study

(2020) Alexander C. Perino et al.   JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY

Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials

(2020) Nan-Nan Shen et al.   Frontiers in Cardiovascular Medicine

Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation

(2019) Piyameth Dilokthornsakul et al.   Heart Lung and Circulation

Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia

(2019) Ahmad S. Hersi et al.   ANNALS OF SAUDI MEDICINE

Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding

(2018) Alexa R. Hospodar et al.   American Journal of Cardiovascular Drugs

Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data

(2017) Jee-Ae Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective

(2016) Kostas Athanasakis et al.   American Journal of Cardiovascular Drugs

Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation

(2016) Ying Jiao Zhao et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial

(2015) Elizabeth A. Magnuson et al.   AMERICAN HEART JOURNAL

Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting

(2015) Kostas Athanasakis et al.   CLINICAL DRUG INVESTIGATION

QALYs in cost-effectiveness analysis: an overview for cardiologists

(2015) Olivier J Wouters et al.   HEART

Trends in Hospitalization for Atrial Fibrillation: Epidemiology, Cost, and Implications for the Future

(2015) Azfar Sheikh et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients

(2015) Gregory Y.H. Lip et al.   STROKE

The Clinical Profile and Pathophysiology of Atrial Fibrillation

(2014) Jason Andrade et al.   CIRCULATION RESEARCH

Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin

(2014) Thitima Kongnakorn et al.   CLINICAL DRUG INVESTIGATION

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

(2014) T. Lanitis et al.   JOURNAL OF MEDICAL ECONOMICS

Cost–Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting

(2013) Bin Wu et al.   CARDIOVASCULAR DRUGS AND THERAPY

Quality of life after TIA and stroke: Ten-year results of the Oxford Vascular Study

(2013) R. Luengo-Fernandez et al.   NEUROLOGY

Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants

(2013) Charalampos Kasmeridis et al.   PHARMACOECONOMICS

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation

(2012) Soyon Lee et al.   PLoS One

Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States

(2011) Michael H. Kim et al.  

The cost of illness of atrial fibrillation: a systematic review of the recent literature

(2011) S. E. Wolowacz et al.   EUROPACE

Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications

(2008) J. Schmitt et al.   EUROPEAN HEART JOURNAL